Tianjin Institute of Pharmaceutical Research

Tianjin Institute of Pharmaceutical Research Co., Ltd.

Bingni Liu

Lida Tang

Peng Liu

Weiren Xu

Yuli Wang

Guilong Zhao

Wei Liu

Meixiang Zou

Wei Wei

Yuqiang Liu

Yafei Xie

Chubing Tan

Jiajia Hou

Wen Du

Jiang Wu

Yuquan Li

Shijun Zhang

Xuyuan Liu

Ying Liu

Hua Shao

Yingmei Han

Guangping Xia

Naxia Zhao

Qian Shang

Changjiang Huang

Weiling Kong

Jing Jin

Xiaohua Kong

Dengke Liu

Nan Yue

Furong Chen

Yunsong Zhou

Yigui Zhao

Deguang Zhi

Mo Liu

Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: wherein the definitions of X, X, X, X, X, X, X, X, X, X, X, X, X, Xand Xare consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.

Glucagon-derived peptide and use thereof

The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R-Rare as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof. 

Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof

Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof

The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of Rand Rare selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H. 

Phenyl C-glucoside derivatives, preparation methods and uses thereof

A compound with the structure of the formula (I) or a pharmaceutically acceptable salt, a preparation method and use thereof are disclosed in the present invention, wherein R is cyano group. The compound provided by the present invention has an antiplatelet aggregation activity and can be used in preparing a medicament for preventing or treating cardiac and cerebral vascular diseases such as coronary artery syndromes, myocardial infarction and myocardial ischemia which are caused by platelet aggregation. 

Thienopyridine ester derivative containing cyano group, preparation method, use and composition thereof

Growing community of inventors

Tianjin, China

Bingni Liu